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Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed
death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared
outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated
survival data.
Patients and methods: PD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected
tumor samples. Patients received pembrolizumab 2 or 10mg/kg Q3W or docetaxel 75mg/m2 Q3W for 24months or until
progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9weeks, survival every 2months.
Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS)50% and1%;
pembrolizumab doses were pooled in this analysis.
Results: At date cut-off of 24 March 2017, median follow-up was 31months (range 23–41) representing 18 additional months
of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously
treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients
analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately
40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS50%. For TPS50%, the OS HRs were 0.64
(95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS1%,
OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS
50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In
patients with TPS1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI:
0.68, 1.02)].
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Conclusion: Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of
patients with newly collected and archival samples.
Trial registration: ClinicalTrials.gov: NCT01905657.
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Introduction
Pembrolizumab is a humanized monoclonal antibody against
programmed death-1 protein (PD-1) that blocks the interaction
between PD-1 and its ligands, PD-L1 and PD-L2.
Pembrolizumab monotherapy is currently approved in several
countries, including the United States, Europe and Japan, for the
first-line treatment of patients with metastatic non-small-cell
lung cancer (NSCLC) whose tumors express high levels of PD-L1
[i.e. tumor proportion score (TPS)50%]; and for the treatment
of patients with metastatic NSCLC with TPS 1% and disease
progression on/after platinum-containing chemotherapy. A
companion diagnostic test [PD-L1 IHC 22C3 pharmDx assay;
Agilent Technologies (formerly Dako), Carpinteria, CA] is
approved to aid in selection of patients with NSCLC for pembro-
lizumab treatment based on PD-L1 expression in formalin-fixed,
paraffin-embedded tumor samples [1]. This assay utilizes quali-
tative immunohistochemistry (IHC) and the murine 22C3 anti-
human PD-L1 monoclonal antibody to detect and score levels of
PD-L1 expression on tumor cells [2]. PD-L1 expression is meas-
ured as the TPS, defined as the percentage of tumor cells with
membranous PD-L1 staining of any intensity.
In the randomized, phase II/III KEYNOTE-010 study, pem-
brolizumab 2 and 10mg/kg given every 3weeks (Q3W) demon-
strated superior overall survival (OS) over standard-of-care
docetaxel treatment in patients with previously treated, PD-L1-
positive NSCLC [3]. This study enrolled 1034 patients with TPS
1%, with the final 593 enrolled patients stratified by TPS 1%–
49% and 50%. The primary results showed median OS in the
total population (i.e. TPS1%) was higher for both pembrolizu-
mab doses compared with docetaxel [10mg/kg: 12.7 versus
8.5months; hazard ratio (HR) 0.61, P< 0.0001; 2mg/kg: 10.4
versus 8.5months; HR 0.71, P¼ 0.0008]. Likewise, for patients
with at least 50% tumor cells expressing PD-L1, OS was signifi-
cantly longer with pembrolizumab 2mg/kg (14.9 versus
8.2months; HR 0.54, P¼ 0.0002) and 10mg/kg (17.3 versus
8.2months; HR 0.50, P< 0.0001) than with docetaxel. With re-
spect to progression-free survival (PFS) in the total population
(i.e. TPS1%), there was no significant difference for either dose
of pembrolizumab compared with docetaxel (10mg/kg: 4.0 ver-
sus 4.0months; HR 0.79, P¼ 0.004; 2mg/kg: 3.9 versus
4.0months; HR 0.88, P¼ 0.07). Furthermore, PFS was improved
in the TPS 50% subset of studied patients receiving pembroli-
zumab 2mg/kg (5.0 versus 4.1months; HR 0.59, P< 0.0001) and
10mg/kg (5.2 versus 4.1months; HR 0.59, P< 0.0001) compared
with docetaxel. Initially, any tumor sample (i.e. archival or newly
collected) was permitted for PD-L1 testing in KEYNOTE-010.
Based on epidemiology data suggesting some discordance be-
tween PD-L1 expression levels in pretreatment surgical tumor
specimens and specimens collected at time of relapse (surgical
tumor specimens or core needle biopsy samples), the study
protocol was later amended to require PD-L1 assessment in
newly collected tumor samples except when it risked patient
safety [4]. Unlike other well-known oncological biomarkers, PD-
L1 tumor expression is dynamic and may be affected by previous
treatment or disease stage [5–9]. Given that previously collected
archival tissue is often the most convenient and easily accessible
tissue source for biomarker testing in the second-line setting, the
determination of whether archival samples can be substituted for
those collected contemporaneously is an important question as it
relates to identifying patients with a greater likelihood of re-
sponse to pembrolizumab. Thus, the current analysis was under-
taken to compare the treatment response to pembrolizumab by
PD-L1 expression in archival and newly collected tumor samples
in the KEYNOTE-010 study. Specifically, the primary objectives
of this pre-specified, exploratory analysis were to (i) compare the
prevalence of PD-L1 TPS 50% and 1% in archival versus
newly collected tumor samples and (ii) evaluate the relative clin-
ical benefit of pembrolizumab over docetaxel for OS, PFS and
overall response rate (ORR) based on archival and newly col-
lected tumor samples using updated survival data from
KEYNOTE-010. The ability to use archival samples instead of
newly collected samples for the determination of PD-L1 expres-
sion would expedite treatment decisions and improve patient
care.
Methods
Study design
KEYNOTE-010 (ClinicalTrials.gov identifier, NCT01905657) is an inter-
national, open-label, phase II/III study of pembrolizumab versus doce-
taxel that randomized 1034 patients with previously treated advanced
NSCLC with a PD-L1 TPS 1% between 28 August 2013 and 27
February 2015 [3]. Patients were randomized (1 : 1 : 1) to one of the two
doses of pembrolizumab (2mg/kg or10 mg/kg Q3W administered intra-
venously over 30min for a maximum of 24months) or docetaxel (75mg/
m2 Q3W administered intravenously over 1 h for the maximum number
of cycles permitted by the local regulatory authorities). Patients were
treated until confirmed disease progression, intolerable toxicity, patient
withdrawal or physician decision. Patients were stratified by Eastern
Oncology Cooperative Group (ECOG) performance status (0 versus 1)
and region (East Asia versus non-East Asia). A third stratification vari-
able, extent of PD-L1 expression (TPS 50% versus 1%–49%), was
added after 441 patients were allocated and the PD-L1 IHC assay cut
point was established in KEYNOTE-001 study.
Patients
Eligible patients (18 years) had locally advanced or metastatic NSCLC
with progression as per Response Evaluation Criteria in Solid Tumors,
version 1.1 (RECIST v1.1) after 2 cycles of platinum-doublet chemo-
therapy, as well as an appropriate tyrosine kinase inhibitor (TKI) for
those with EGFR-sensitizing mutation or ALK gene rearrangement;
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measurable disease as per RECIST; ECOG performance status of 0–1;
provision of a signed informed consent and a tumor sample with PD-L1
TPS 1%. Initially, any tumor sample was permitted for PD-L1 testing;
however, the study protocol was later amended to require a newly col-
lected tumor sample except when it risked patient safety. To be consid-
ered a newly collected sample, it was required to be from a recent biopsy
with no intervening treatment between the time of sample collection and
the initiation of study therapy. The only exception was patients on a TKI
before biopsy collection. They could resume that agent after the biopsy.
Key exclusion criteria included previous treatment with PD-1 checkpoint
inhibitors or docetaxel, known active brain metastases, history of pneu-
monitis or active autoimmune disease.
PD-L1 status for eligibility was assessed using the anti-PD-L1 antibody
clone 22C3 (Merck & Co. Inc., Kenilworth, NJ) and a clinical trial version
of the approved IHC assay (pharmDx assay; Dako, Carpinteria, CA). PD-
L1 positivity was defined asmembranous staining on at least 1% of tumor
cells [10].
End points
In the previous report, primary end points included OS (i.e. time from
randomization to death due to any cause) and PFS (time from random-
ization to radiologically confirmed progressive disease or death due to
any cause) both in the total population (i.e. TPS 1%) and in the TPS
50% stratum for both pembrolizumab doses [3]. Secondary end points
included ORR and duration of response in the TPS1% population and
50% stratum. Exploratory end points included evaluation of OS and
PFS in patients enrolled based on archival and newly collected tumor
samples. Because OS and PFS results were similar between pembrolizu-
mab doses for the primary end points [3], the 2 and 10mg/kg doses were
pooled for the purpose of the current analysis to minimize variability.
Assessments
Tumor response was assessed every 9weeks per RECIST, v1.1 by inde-
pendent central review [11]. Survival was assessed every 2months after
treatment discontinuation.
Statistics
The Kaplan–Meier method was used to estimate OS and PFS in the arch-
ival and newly collected sample populations. For OS, data for patients
who were alive or lost to follow-up were censored at the time of last con-
firmed contact. For PFS, data for patients who had not progressed or
were lost to follow-up were censored at the time of last tumor assessment.
The proportions of patients with archival and newly collected tumor
samples were tallied and summated using summary statistics. A stratified
Cox proportional hazard model with Efron’s method of tie handling was
used to calculate HRs and associated 95% confidence intervals (CIs).
Statistical analyses were carried out using SAS (version 9.3).
Results
Subject characteristics
Baseline demographics and disease characteristics were similar
for patients enrolled in the combined pembrolizumab groups
and the docetaxel group (Table 1). One patient was excluded
from the efficacy analysis because it was not possible to assess
tumor response due to GCP noncompliance at the study site. Of
the 1033 patients analyzed, 455 (44%) were enrolled based on
archival samples and 578 (56%) on newly collected tumor sam-
ples. The proportions of patients enrolled based on archival sam-
ples occurred with a similar frequency in patients with squamous
and nonsquamous histology (Figure 1A). The median time be-
tween sample collection and PD-L1 assessment was 250 days
(range 3–2510) for archival samples and 11 days (range 1–371)
for new samples. Approximately 40% of archival samples and
45% of newly collected tumor samples were PD-L1 TPS 50%
(Figure 1B). The data in this report were analyzed using a cut-off
date of 24 March 2017 [median follow-up 31months (range 23–
41)]. Patients with newly collected tumor samples [28months
(range 24–41)] had a shorter mean follow-up time versus those
with archival samples [34months (range 24–41)] due to the
protocol amendment (see above).
Outcome analysis
Kaplan–Meier estimates of OS for the overall population of
patients with TPS 50%, TPS 1% and TPS 1%–49% irrespect-
ive of sample type are shown in Figure 2A, C and E, respectively.
For patients with TPS50%, the OS HR was 0.50 (95% CI: 0.39,
0.64) favoring pembrolizumab over docetaxel. Themedian values
were 17.1months (95% CI: 12.4, 21.8) and 8.2months (95% CI:
6.6, 10.4), respectively. For patients with TPS1%, the OS HR is
0.66 (95% CI: 0.57, 0.77) favoring pembrolizumab over docetaxel
with median values of 11.9months (95% CI: 10.4, 13.3) and
Table 1. Baseline demographics and disease characteristics in the overall
PD-L1 TPS 1% population
Characteristic, n (%) Pembrolizumaba
N5 690
Docetaxelb
N5343
Age, median (range), years 63 (20–88) 62 (33–82)
Men 425 (62) 209 (61)
ECOG performance status
0 232 (34) 116 (34)
1 454 (66) 224 (65)
2 4 (<1) 2 (<1)
Smoking history
Current or former 564 (82) 269 (78)
Never 123 (18) 67 (20)
Unknown 3 (<1) 7 (2)
Histology
Squamous 156 (23) 66 (19)
Nonsquamous 484 (70) 240 (70)
Other/not speciﬁed 50 (7) 37 (11)
EGFR-sensitizing mutation 60 (9) 26 (8)
ALK translocation 6 (<1) 2 (<1)
No. of lines of previous treatment
Neoadjuvant 2 (<1) 0
Adjuvant 13 (2) 3 (<1)
1 478 (69) 235 (69)
2 196 (28) 104 (30)
Unknown 1 (<1) 1 (<1)
aCombined data across the 2 and 10mg/kg dose.
bOne patient in the docetaxel arm had an unknown ECOG performance
status; for ﬁve of the six patients who had and ECOG performance status
2 during screening, the score improved to 1 by the time the patients
were randomly allocated to treatment.
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8.6months (95% CI: 7.9, 9.8), respectively. For patients with TPS
1%–49%, the OS HR is 0.76 (95% CI: 0.62, 0.92) with median
values of 10.2months (95% CI: 9.3, 11.8) and 8.7months (95%
CI: 8.0, 10.7), respectively.
Kaplan–Meier estimates of OS for the populations of patients
with TPS50% and1% and further analyzed by archival versus
newly collected tumor samples are shown in Figure 3. For TPS
50% patients enrolled based on PD-L1 expression in archival
samples, the OS HR was 0.64 (95% CI: 0.45, 0.91) favoring pem-
brolizumab over docetaxel. The median values were 11.8months
(95% CI: 9.0, 15.9) and 7.5months (95% CI: 4.6, 12.2), respect-
ively (Figure 3A). For TPS 50% patients enrolled based on PD-
L1 expression in new samples, the OS HR was 0.40 (95% CI: 0.28,
0.56), with median values of 28.1months (95% CI: 17.1, NR) and
8.3months (95% CI: 6.3, 11.7), respectively (Figure 3B). For TPS
1% patients enrolled based on PD-L1 expression in archival
samples, the OS HR was 0.74 (95% CI: 0.59, 0.93) favoring pem-
brolizumab with median values of 10.5months (95% CI: 9.3,
12.0) and 8.5months (95% CI: 7.3, 9.9), respectively (Figure 3C).
For TPS 1% patients enrolled based on PD-L1 expression in
new samples, the OS HR was 0.59 (95% CI: 0.48, 0.73), with me-
dian values of 13.3months (95% CI: 11.2, 17.1) and 8.7months
(95%CI: 7.6, 10.7), respectively (Figure 3D).
Kaplan–Meier estimates of PFS for the overall population of
patients with TPS50%,1% and 1%–49% irrespective of sam-
ple type are shown in Figure 3B, D and F, respectively. For
patients with TPS 50%, the PFS HR was 0.58 (95% CI: 0.46,
0.73) favoring pembrolizumab over docetaxel. Themedian values
were 5.3months (95% CI: 4.2, 6.7) and 4.1months (95% CI: 3.6,
4.6), respectively. For patients with TPS1%, the PFS HR is 0.83
(95% CI: 0.72, 0.96) with median values of 3.9months (95% CI:
3.1, 4.1) and 4.1months (95% CI: 3.6, 4.3), respectively. For
patients with TPS 1%–49%, the PFS HR is 1.02 (95% CI: 0.85,
1.24) with median values of 2.6months (95% CI: 2.1, 3.4) and
4.1months (95%CI: 2.7, 5.4), respectively.
Kaplan–Meier estimates of PFS for the populations of patients
with TPS50% and1% and further analyzed by archival versus
newly collected tumor samples are shown in Figure 4. When eval-
uated in patients with TPS 50%, PFS was observed to be longer
with pembrolizumab than docetaxel, irrespective of whether
patients were enrolled based on archival or newly collected tumor
samples. In archival sample patients, the PFS HR was 0.63 (95%
CI: 0.45, 0.89) with median values of 4.0month for each treat-
ment. In new sample patients, the PFS HR was 0.53 (95% CI:
0.38, 0.72) with median values of 6.9months for pembrolizumab
and 4.3months for docetaxel (Figure 4A and B). When evaluated
in patients with TPS 1%, there was no difference in PFS be-
tween pembrolizumab and docetaxel irrespective of whether
patients were enrolled based on archival or newly collected tumor
samples. In archival sample patients, the PFS HRs were 0.82 (95%
CI: 0.66, 1.02) and 0.83 (95%CI: 0.68, 1.02) in patients with arch-
ival and new samples, respectively, with median values that
ranged from 3.1 to 4.2months for both treatments (Figure 4C
and D).
In both the TPS 50% and TPS1% populations irrespective
of sample type, pembrolizumab led to a greater improvement in
ORR compared with docetaxel (Figure 5). For the TPS 50%,
the ORR was 32.4% (94/290; 95% CI: 27.1, 38.1) for pembrolizu-
mab versus 8.6% (13/152; 95% CI: 4.6, 14.2) for docetaxel. For
the TPS 1%, the ORR was 20.9% (144/690; 95% CI: 17.9, 24.1)
for pembrolizumab versus 9.3% (32/343; 95% CI: 6.5, 12.9) for
docetaxel. When analyzed across the individual populations
defined by TPS 1%/50% and archival/newly collected tumor
samples, improvements in ORR were observed with pembrolizu-
mab versus docetaxel for all populations examined except for
patients with TPS 1% and archival samples. In the docetaxel
group, similar proportions of patients had responses ranging
from8% to10% across the individual populations. For pem-
brolizumab, the ORR was 15.7% (47/300; 95% CI: 11.7, 20.3) for
patients with TPS 1% and archival samples, 22.7% (27/119;
95% CI: 15.5, 31.3) for patients with TPS 50% and archival
samples, 24.9% (97/390; 95% CI: 20.7, 29.5) for patients with
TPS 1% and newly collected tumor samples, and 39.2% (67/
171; 95% CI: 31.8, 46.9) for patients with TPS 50% and newly
collected tumor samples.
Discussion
The amount of PD-L1 expression may theoretically change over
time. The question is whether this happens with sufficient magni-
tude and with sufficient frequency that newly acquired tissue is
mandatory. The motivation for this analysis was in large part an
attempt to answer this question. Cho et al. [4] attempted to ad-
dress this question by looking at the change in PD-L1 status
(using 22C3) in paired lung samples but could not directly assess
the predictive value of PD-L1 status for response to pembrolizu-
mab. Temporal effects, along with spatial tumor heterogeneity
and analytical factors, represent unavoidable practical limitations
Squamous (n = 222)
A
B
Nonsquamousa  (n = 811)
aIncludes patients with mixed, other, or unknown histology
Archival
New
TPS ≥50%
TPS 1%-49%
Archival (n = 455)
52% 48% 57% 43%
60% 40% 55% 45%
New (n = 578)
Figure 1. (A) Prevalence of archival and newly collected tumor sam-
ples used for assessment of PD-L1 expression by histology. (B)
Prevalence of PD-L1 TPS 50% and TPS 1%–49% in archival and
newly collected tumor samples.
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for assessing PD-L1 status. In addition, other, more subtle factors
may also come into play. For the most part, newly acquired biop-
sies were obtained primarily to assess PD-L1 status, and thus test-
ing was assessed on a more optimal section from the block, more
representative of PD-L1 expression by the total body burden of
tumor. Conversely, PD-L1 testing from archival biopsies may
often be assessed from tissue blocks which are nearly exhausted,
and thus contain a minimal amount of tissue.
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Figure 2. Kaplan–Meier estimates of (A) overall survival (OS) and (B) progression-free survival (PFS) for the ITT population (TPS 50%), and
(C) OS and (D) PFS for the ITT population (TPS 1%) and (E) OS and (F) PFS for the ITT population (TPS 1%–49%). ITT, intention to treat.
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Prior studies have demonstrated a clear association between
PD-L1 tumor expression and antitumor efficacy of pembrolizu-
mab in patients with metastatic NSCLC [3, 10]. The KEYNOTE
010 study demonstrated improved OS, PFS and ORR with pem-
brolizumab over docetaxel in patients with PD-L1 positive, re-
fractory NSCLC in the primary analysis (using data cut point of
30 September 2015 representing13.1months of follow-up) [3],
for patients in the TPS 50% stratum, and improved OS for
patients in the TPS 1% population. The final 442 patients were
enrolled into strata based on a PD-L1 expression level of 1%–
49% or50% as assayed in either an archival or recently collected
tumor sample. One remaining question that has not yet been
evaluated to date is the comparability of the treatment response
to pembrolizumab in patients with archival and newly collected
tumor samples by PD-L1 expression. The ability to utilize arch-
ival tumor samples for assaying PD-L1 expression instead of
requiring newly collected tumor samples would greatly benefit
patient health and streamline treatment decisions. Thus, this pre-
specified exploratory analysis examined OS, PFS and ORR in pa-
tient populations defined based on PD-L1 expression (TPS 1%
and50%) and tumor sample type (archival and newly collected
tumor samples) using the updated data cut point of 24 March
2017 (additional 18months of follow-up from primary analysis).
The results of this analysis show that the distributions of PD-
L1 expression levels (i.e. TPS 1% and 50%) were similar
among both archival (60% and 45%, respectively) and newly col-
lected (55% and 45%, respectively) tumor samples. This finding
demonstrates that PD-L1 expression was adequately preserved
following months of storage (median 8months between sample
collection and assay) and was possibly unaffected by initiation of
additional treatments following tumor sample collection, and
potentially worsening disease stage. Additionally, similar propor-
tions of patients with squamous and nonsquamous histology
were enrolled based on archival and newly collected tumor
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samples showing there was no obvious baseline imbalance related
to tumor histology that may have skewed the analysis results.
Treatment with pembrolizumab provided an OS benefit rela-
tive to docetaxel in the overall study population as well as patients
with TPS1% and50% regardless of the age of the tumor sam-
ple. Within both the archival and newly collected tumor sample
populations, a trend toward longer OS was observed in patients
with TPS50% versus1%. The fact that the newly acquired bi-
opsy was somewhat more predictive may reflect the fact that
the newly acquired biopsy better reflects the PD-L1 status of the
tumor at the time of treatment. However, this does not negate the
validity of using archival biopsies to assess PD-L1 status. This
finding is consistent with the results seen in the overall study
population [10]. Similarly, OS appeared more pronounced in the
newly collected tumor sample versus archival populations when
examined within each of the TPS1% and TPS50% categories.
Although the OS survival benefit appeared numerically greater in
patients with newly collected tumor samples, the CIs for the HRs
excluded 1.0 and overlapped across all the patient populations
examined in this analysis. Median OS with pembrolizumab
ranged from 10.5 to 28.1months. In contrast, median OS with
docetaxel was similar across the patient populations, with a me-
dian survival time ranging from 7.5 to 8.7months, which is con-
sistent with that reported in a previous study (9months) [12].
With regard to PFS and ORR, improved outcomes were
observed with pembrolizumab over docetaxel in patients with
TPS 50% regardless of whether PD-L1 expression was assessed
in archival or newly collected tumor samples. By comparison, the
PFS and ORR benefit of pembrolizumab appeared less pro-
nounced in patients with TPS1% across the archival and newly
collected tumor sample populations. This is consistent with the
findings in the overall study population [10]. Given that OS with
pembrolizumab was improved relative to docetaxel across all PD-
L1 expression and tumor sample populations, these data suggest
that PFS may not appropriately reflect the true benefit of anti-
PD-1 treatment. A previous study of nivolumab and docetaxel in
patients with nonsquamous NSCLC also reported the lack of a
PFS benefit despite a significant improvement in OS [13].
Although the results of this analysis are compelling, several
limitations should be considered before extrapolating these find-
ings more broadly. The Blueprint PD-L1 ICH Assay Comparison
Project recently showed variability in the clinical diagnostic per-
formance of the four PD-L1 IHC assays used in clinical trials of
patients with NSCLC [14]. Despite similar analytical performan-
ces of various PD-L1 expression assays, interchanging the assays
and cutoff values resulted in misclassification of PD-L1 status in
some patients. This finding suggests that the TPS cutoff values
used in the current analysis may not be broadly applicable to
other PD-L1 IHC assays. While it is tempting to attribute
between-assay discordance to short-term sources of variation
(analytical run-to-run, pathologist read-to-read, block section-
to-section), differences in the stability of assay target antigens
may also come into play. The Blueprint Project does not address
this issue, and the rationale for using archival samples critically
depends on antigen stability. Therefore, the ability of archival
samples to accurately predict response to treatment can only be
extrapolated to the IHC 22C3 assay at this point in time. Future
analyses are needed to determine whether similar findings are
observed for different PD-L1 assays. In addition, a recent study
showed heterogeneity in PD-L1 expression within fields of view
of the same tumor sample, suggesting that a minimal representa-
tive area (not yet determined) must be sampled to accurately pre-
dict response to therapy [15]. Therefore, it is possible that
differences in heterogeneity within archival versus newly col-
lected tumor samples may limit the applicability of these
findings.
The situation has become much simpler now that pembrolizu-
mab is approved for first-line treatment. Even if there are mul-
tiple biopsies, the temporal effects are minimal. The interval
between biopsies will be relatively short, there is no intervening
therapy, and other factors such as total tumor body burden and
immune exhaustion do not come into play. Furthermore, pem-
brolizumab itself has become standard of care, so assessment of
PD-L1 expression is prioritized along with other testing (e.g.
EGFR mutations and ALK gene rearrangements), and PD-L1 is
carried out on more optimal tissue sections. The most important
factor for making first-line treatment decisions is to perform PD-
L1 testing on an optimal tissue section, i.e. one containing as
many viable tumor cells as possible.
In conclusion, the results of this analysis show the OS benefit
of pembrolizumab over docetaxel for both TPS 50% and TPS
1%, regardless of whether PD-L1 was assessed in archival or
newly collected tumor samples. Compared with newly collected
tumor samples, archival samples were not associated with loss of
PD-L1 expression and thereby enabled an accurate estimation of
response to treatment. Although there appeared to be a more
pronounced clinical benefit in the TPS 50% stratum based on
newly collected tumor samples, there was still clinical benefit
when TPS was determined from archival specimens. Newly diag-
nosed patients with advanced NSCLC should be evaluated for
PD-L1 using the 22C3 antibody. Whether to obtain a new biopsy
in such a setting can be discussed with patients with the know-
ledge that clinical benefit was observed with archival biopsies.
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